De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease

ConclusionsDarbepoetin alfa can be safely administered either QW or Q2W to ESA-na ïve pediatric patients with CKD-related anemia to achieve Hb targets of 10.0–12.0 g/dl.

Source: Pediatric Nephrology - August 17, 2017 Category: Urology & Nephrology Source Type: research